Loading
Adding durvalumab and bevacizumab to chemoembolisation lengthened the time to progression by about seven months in liver cancer suitable for embolisation, the first systemic combination to improve on chemoembolisation alone.
Phase 3 placebo-controlled trial of 616 patients with unresectable hepatocellular carcinoma eligible for embolisation randomised to transarterial chemoembolisation with durvalumab plus bevacizumab, durvalumab alone, or placebo.
Median progression-free survival was 15.0 months with durvalumab plus bevacizumab against 8.2 months with placebo (hazard ratio 0.77), while durvalumab alone did not significantly improve progression-free survival; grade 3 to 4 adverse events were more frequent with the combination.
Chemoembolisation combined with durvalumab and bevacizumab is a new option for intermediate-stage hepatocellular carcinoma where approved, though overall survival benefit is not yet shown.
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
Shares EMERALD-1, Intermediate hepatocellular carcinoma (BCLC B).
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
Shares EMERALD-1, Intermediate hepatocellular carcinoma (BCLC B).
Shares Intermediate hepatocellular carcinoma (BCLC B), Durvalumab.
Shares Durvalumab, Bevacizumab.
Shares The Lancet, Bevacizumab.
Shares Durvalumab, Bevacizumab.